anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject medicine having preventive and treating effects effective against all influenza viruses without relating to the antigenic variation of the viruses by including glucoproteins obtained from the cell membranes of avian erythrocytes. SOLUTION: Avian erythrocytes are separated from avian blood, hemolyzed in a 0.5% acetic acid solution, and subsequently centrifuged. The obtained cell membranes of the avian erythrocytes are subjected to an extraction method, a phenol distribution method, an ethanol precipitation method, a dialysis method, a lyophilization method, etc. The obtained glycoproteins contain a glycoprotein having a mol.wt. of >=100,000 and a glycoprotein having a mol.wt. of <=35,000, and contain sugar chains which are receptors capable of binding to influenza viruses. The glycoproteins are processed to obtain the objective influenza virus medicine containing the glycoproteins as active ingredients and not affected by the antigenic variation of the virus.
Integrins are a large family of cell adhesion molecules involved in tumor cell differentiation, migration, proliferation and neovascularization. Tumor cell‑derived exosomes carry a large number of integrins, which are closely associated with tumor progression. As crucial mediators of intercellular communication, exosomal integrins have gained attention in the field of cancer biology. The present review examined the regulatory mechanisms of exosomal integrins in tumor cell proliferation, migration and invasion, and emphasized their notable roles in tumor initiation and progression. The potential of exosomal integrins as drug delivery systems in cancer treatment was explored. Additionally, the potential of exosomal integrins in clinical tumor prediction was considered, while summarizing their applications in diagnosis, prognosis assessment and treatment response prediction. Thus, the present review aimed to provide guidance and insights for future basic research and the clinical translation of exosomal integrins. The study of exosomal integrins is poised to offer new perspectives and methods for precise cancer treatment and clinical prediction.
Factor VIII Assays

Factor VIII activity produced by ROCTAVIAN in human plasma is higher if measured with OSA compared to CSA. In clinical studies, there was a high correlation between OSA and CSA factor VIII activity levels across the entire range of each assay's results [doi: 10.1182/blood.2020005683]. For routine clinical monitoring of factor VIII activity levels, either assay may be used. The conversion factor between the assays can be approximated based on clinical study results (central laboratory) to be: OSA = 1.5 × CSA. For example, a factor VIII activity level of 50 IU/dL using CSA calculates to a level of 75 IU/dL using OSA. The OSA to CSA ratio depends on the factor VIII assay reagents used by the laboratory and can range from 1.3 to 2.0, therefore, the same type of OSA or CSA reagents should be used to monitor factor VIII levels over time.

When switching from hemostatic products prior to ROCTAVIAN treatment, physicians should refer to the relevant prescribing information to avoid the potential for factor VIII activity assay interference during the transition period.

Factor VIII Inhibitors

Monitor patients through appropriate clinical observations and laboratory tests for the development of factor VIII inhibitors after ROCTAVIAN administration. Perform an assay that detects factor VIII inhibitors if bleeding is not controlled, or plasma factor VIII activity levels decrease [see Dosage and Administration (2.3)].
BACKGROUND: This study delves into the complex interplay among prostate-specific antigen, alkaline phosphatase, and the temporal dynamics of tumor shrinkage in prostate cancer. By investigating the longitudinal trajectories and time-to-prostate cancer tumor shrinkage, we aim to untangle the intricate patterns of these biomarkers. This understanding is pivotal for gaining profound insights into the multifaceted aspects of prostate cancer progression. The joint model approach serves as a comprehensive framework, facilitating the elucidation of intricate interactions among these pivotal elements within the context of prostate cancer .
METHODS: A new joint model under a shared parameters strategy is proposed for mixed bivariate longitudinal biomarkers and event time data, for obtaining accurate estimates in the presence of missing covariate data. The primary innovation of our model resides in its effective management of covariates with missing observations. Built upon established frameworks, our joint model extends its capabilities by integrating mixed longitudinal responses and accounting for missingness in covariates, thus confronting this particular challenge. We posit that these enhancements bolster the model's utility and dependability in real-world contexts characterized by prevalent missing data. The main objective of this research is to provide a model-based approach to get full information from prostate cancer data collected with patients' baseline characteristics ( Age  , body mass index ( BMI  ), GleasonScore  , Grade  , and Drug  ) and two longitudinal endogenous covariates ( Platelets  and Bilirubin  ).
RESULTS: The results reveal a clear association between prostate-specific antigen and alkaline phosphatase biomarkers in the context of time-to-prostate cancer tumor shrinkage. This underscores the interconnected dynamics of these key indicators in gauging disease progression.
CONCLUSIONS: The analysis of the prostate cancer dataset, incorporating a joint evaluation of mixed longitudinal prostate-specific antigen and alkaline phosphatase biomarkers alongside tumor status, has provided valuable insights into disease progression. The results demonstrate the effectiveness of the proposed joint model, as evidenced by accurate estimates. The shared variables associated with both longitudinal biomarkers and event times consistently deviate from zero, highlighting the robustness and reliability of the model in capturing the complex dynamics of prostate cancer progression. This approach holds promise for enhancing our understanding and predictive capabilities in the clinical assessment of prostate cancer.
The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise of the neck and shoulder) and TENS (Transcutaneous electrical nerve stimulation) applications on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist.
Recent findings in HF suggest an altered effect of group III/IV muscle afferents in this population. Although normal afferent feedback is crucial for adequate O2 delivery during exercise, excessive neural feedback has substantial negative consequences. HF patients are characterized by augmented neural feedback arising from overactive muscle afferents. It has been hypothesized that this abnormality compromises locomotor muscle O2 delivery in these patients. Therefore, the abnormally elevated muscle afferent feedback in HF might exacerbate, compared to healthy age- and activity matched individuals (CTRLs), the development of both peripheral (via limiting O2 delivery) and central (via restricting CMD) fatigue during exercise. Recent advances in non-invasive stimulation techniques offer a genuine opportunity to identify the sites and synaptic mechanisms that mediate central and peripheral fatigue including alterations in the responsiveness of the corticospinal tract (i.e. a determinant of central fatigue). Taken together, the proposed studies aim to determine the impact of HF on the precise development of central and peripheral fatigue during both whole body and single muscle exercise and evaluate the extent to which group III/IV muscle afferents contribute to this development.
The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.
Volunteers with type 2 diabetes mellitus will be evaluated in terms of any contra-indication that will restrain them from making exercise. 90 male or female volunteers who are suitable in terms of inclusion/exclusion criteria will be invited for the study. Volunteers will be randomly distributed to one of the 3 groups. Each group will contain 30 participants. 1. group will make aerobic exercise which is in the form of high intensity interval exercise 2.group will make aerobic exercise which is in the form of moderate intensity continuous exercise 3. Control group. Exercise groups will be cycling under observation in the hospital setting. Control group will make simple stretching exercises at home. Participants will be requested to complete a 3 months of exercise. They will be evaluated before and at the end of the 3 months of exercise with basic gait parameters such as cadence, gait speed, stride length, percentages of swing phase and stance phase evaluated by a wireless digital miniature gait analysis system.
A system and method tracks medical articles and containers by providing a robust electromagnetic (EM) field within an enclosure in which the articles and containers are stored. Respective data carriers, such as RFID tags, attached to each article or container respond to the electromagnetic field by transmitting unique identification data. A data base associates the data carrier identification data with data about the medical articles or containers including type of medicine, size of the dose, and expiration date. A processor notifies a pharmacy when a medical article is received and when removed. The processor also notifies the finance department regarding patient medical articles and administration to update the patient's Medication Administration Record. The processor also provides inventory level counts and expiration dates.
NEW MATERIAL:An imidazole derivative shown by the formulaI(X and Y are H or nitro; Z is 3-iodopropargyl group; 2,3,3-triiodoallyl). EXAMPLE:1-(3',3',2'-Triiodoallyl)imidazole. USE:Useful as an antibacterial and antifungal agent. Showing growth inhibiting action on a wide range of fungi, effective for improving undesirable conditions caused by growth of bacteria and fungi in the field of medical treatment, agriculture, and industry. For example, useful for disinfection of mechanical tools for medical treatment use, for inhibiting putrefactive microorganisms in service water for agricultural and industrial use. PROCESS:As shown by the formulas, a substituted or unsubstituted imidazole shown by the formula II is reacted with a reactive derivative of 3,3,2-triiodoallyl alcohol shown by the formula III or a reactive derivative of 3-iodopropargyl alcohol shown by the formula IV, to give a compound shown by the formulaI.
The present invention discloses a wet particle process for a cefuroxime axetil tablet. Firstly, 163g cefuroxime axetil, 25g carboxyl methyl starch sodium, 75g starch and 10g lactoseare are selected, followed by crossing the screen with 60 holes and mixing . Secondly, 20g silica gel particle is added and well mixed. Thirdly, 100ml hydroxypropyl methylcellulose of 2 percent is produced into the flexible material and particles are produced by a nylon screen with 16 holes. The product is dried at 60 DEG C for 5 to 6 hours and the particles are selected by a nylon screen with 14 holes. Followed by homogeneous mixing of 25g carboxyl methyl starch sodium, 5g magnesium separate and tabletting the core by 125mg cefuroxime axetil per tablet. Finally, the packaging liquid can spray slowly and the tablet core is dried at 40 DEG CC to 50 DEG C at any time. The packaging liquid for 1000 tablet cores is 100ml pharmaceutical film coating premixed agent of 20 percent. In the wet particle process of the present invention, the carboxymethyl sodium particle is added by internal and external addition. Therefore the tablet core is quickly divided into particles and further divided into thin powder, and then the biological activity is released quickly.
OBJECTIVES: Mutations in the X-linked endosomal Na+/H+ exchanger 6 (NHE6) cause Christianson syndrome (CS). Here, in the largest study to date, we examine genetic diversity and clinical progression in CS into adulthood.
METHOD: Data were collected as part of the International Christianson Syndrome and NHE6 (SLC9A6) Gene Network Study. 44 individuals with 31 unique NHE6 mutations, age 2-32 years, were followed prospectively, herein reporting baseline, 1 year follow-up and retrospective natural history.
RESULTS: We present data on the CS phenotype with regard to physical growth and adaptive and motor regression across the lifespan including information on mortality. Longitudinal data on body weight and height were examined using a linear mixed model. The rate of growth across development was slow and resulted in prominently decreased age-normed height and weight by adulthood. Adaptive functioning was longitudinally examined; a majority of adult participants (18+ years) lost gross and fine motor skills over a 1 year follow-up. Previously defined core diagnostic criteria for CS (present in>85%)-namely non-verbal status, intellectual disability, epilepsy, postnatal microcephaly, ataxia, hyperkinesia-were universally present in age 6-16; however, an additional core feature of high pain tolerance was added (present in 91%). While neurologic examinations were consistent with cerebellar dysfunction, importantly, a majority of individuals (>50% older than 10) also had corticospinal tract abnormalities. Three participants died during the period of the study.
CONCLUSIONS: In this large and longitudinal study of CS, we begin to define the trajectory of symptoms and the adult phenotype thereby identifying critical targets for treatment.
Preoperative education about ERAS program is administered in the ward after admission by a specific team. Breathing training and atomizing during the time of preoperative preparation is performed during hospitalization (5-7 days). Patients are allowed to eat a normal diet and intake of 1000 ml 10% carbohydrate drink 10 hours before surgery and oral 500ml 10% carbohydrate drink 2 hours before the induction of anesthesia. Mechanical bowel preparation is not recommended as routine procedure.

The intravenous fluid therapy is restricted. Urinary catheters are routinely placed after anesthesia. In principle, drainage and nasogastric tube are not placed (except the concerns of surgical safety). Surgical site infiltration is implemented.All patients undergo laparoscopic distal gastrectomy.

Urinary catheters are routinely removed within 24 hours after operation. An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia. Adjunctive analgesia with acetaminophen is used after the resumption of oral intake until adequate pain relief. Patients were encouraged to move from POD 1. The patients are encouraged to a full fluid diet on POD 2. Adhere to the premise of eating little and often daily increase, then to semi-fluids to soft diet. A normal diet is often started on POD 4. Abdominal drains are routinely removed within 72 hours after operation.
This study aimed to investigate the ecological system factors that influence discrimination of sarcopenia among older individuals living in contemporary society. Data analysis included information from 618 older adults individuals aged 65 years or older residing in South Korea. To assess variations in ecological system factors related to SARC-F scores, we conducted correlation analysis and t-tests. Discriminant analysis was used to identify factors contributing to group discrimination. The key findings are summarized as follows. First, significant differences at the p < 0.001 level were observed between the SARC-F score groups in various aspects, including attitudes toward life, wisdom in life, health management, social support, media availability, sports environment, collectivist values, and values associated with death. Further, service environment differences were significant at p < 0.01 level, while social belonging and social activities exhibited significance at p < 0.05. Second, factors influencing group discrimination based on the SARC-F scores were ranked in the following order: health management, attitudes toward life, fear of own death, wisdom in life, physical environment, sports environment, media availability, social support, fear of the own dying, collectivist values, service environment, social activities, and social belonging. Notably, the SARC-F tool, which is used for sarcopenia discrimination, primarily concentrates on physical functioning and demonstrates relatively low sensitivity. Therefore, to enhance the precision of sarcopenia discrimination within a score-based group discrimination process, it is imperative to incorporate ecological system factors that exert a significant influence. These modifications aimed to enhance the clarity and precision of the text in an academic context.
The invention provides polypeptide nanoparticle functionalized hydrogel microspheres, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The invention prepares a micro-point biological material with alpha-helical polypeptide nano particles and anti-inflammatory micelle functionalized hydrogel microspheres. In one aspect, the alpha-helical polypeptide nanoparticles of the microspot biomaterial trigger both disruption of the mitochondrial membrane and disruption of Ca  2+  homeostasis, synergistically inhibit Ca  2+  -dependent N-cadherin expression and fibroblast apoptosis, thereby inhibiting fibroblast cluster migration. On the other hand, the sustained release of solubilized hydrophobic anti-inflammatory agents improves the inflammatory microenvironment. The inhibiting ability to tendon adhesion is also demonstrated in vivo, and the material can promote apoptosis, reduce the expression of vimentin and alpha-SMA, and realize long-term anti-inflammatory effect. The use of the micro-point biomaterial of the invention provides a novel treatment for inhibiting tissue adhesion.
The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
The invention discloses a monoclonal antibody of a novel vascular endothelial growth factor (VEGF). The monoclonal antibody has very high appetency on the VEGF and very low immunogenicity; and the biological activity of the monoclonal antibody is obviously improved. The invention further discloses an application of the monoclonal antibody on the aspects of research and diagnosis treatment. Compared with the positive medicines, the humanized monoclonal antibody (with high specificity) of the vascular endothelial growth factor, provided by the invention, has the advantages of excellent medical effect, simplicity and convenience in a preparation technique, and relatively low cost, and capacity of providing accurate, simple, convenient and effective monitoring means for preventive treatment, early-stage screening and diagnosis, being wide in application range and meeting social demands. Totally, the monoclonal antibody provided by the invention is positively suitable for the working requirements and humanized service requirements in the fields of modern organisms, prevention and healthcare, and clinical diagnosis. The monoclonal antibody as well as preparation method and application refer to researching and developing the humanized monoclonal antibody for the VEGF, and provide a treatment medicine with relatively high cost performance on the medical market, so that a very wide application prospect can be realized.
The disclosure provides a method for providing telehealth services using touchless health vitals and artificial intelligence optimized assessment in real-time. The method includes obtaining real-time video and audio data of a user through a video capturing unit. Health vital signs data of the user are obtained from the real-time video and audio data using a touchless vital monitoring module. A real-time voice tone analysis is performed using a trained data model to identify a plurality of factors associated with the voice of the user and a health condition is determined based on comparing the plurality of factors with a predefined threshold associated with historic conversion data of the user. Health insights for the user are derived based on the health vital signs data and the health condition of the user. The health insights are used by the health care professional for further diagnosis and treatment for the user.
The matter of raising and educating deaf children has been caught up in percepts of development that are persistently inaccurate and at odds with scientific research. These percepts have negatively impacted the health and quality of life of deaf children and deaf people in general. The all too prevalent advice is to raise the child strictly orally and wait to see what happens. Only when the child is seriously behind is a completely accessible language - a sign language - introduced, and that is far too late for protecting cognitive health. The medical profession, along with others, needs to offer parents better advice and better supports so that neither the children nor their parents wait and watch as the oral-only method fails. All must take responsible action to assure an approach that succeeds.
FIELD: agriculture, vaccines. SUBSTANCE: invention relates to a method of poultry vaccination against coccidosis. Method involves administration in ovo of live sporozoites or merozoites or their mixture at effective immunizing dose. In preferable variant hen or turkey is subjected for vaccination. Method provides immunity against coccidosis in hatching chickens. EFFECT: enhanced efficiency of method, increased gain in chickens. 10 cl, 2 ex, 3 tbl
Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.